Under construction – not a live service
Sign in
Taking peopleNo phase

Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients

Key facts

Who runs it
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Where
Limoges, FranceSee the siteAlso in 8 other countries, 22 sites
Trial code
Status
Recruiting
People taking part
100 people, planned
Started
19 Jun 2023
Expected to end
28 Feb 2028
Type of study
Observational
Record updated
15 June 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC
  • Ability to understand the purpose of the study and provide signed and dated informed consent

Who cannot take part

  • Lack of the serological mismatch at transplantation
  • Lack of clinical and/or laboratory data regarding the type of CMV event
  • Lack of the type of SOT or HSCT
  • Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis

Where in France

Also in 8 other countries, 22 sites

  • Centre Hospitalier Universitaire de LimogesLimoges, FranceContact: Sophie AlainNot yet recruiting

About the trial

What the trial wants to find out

The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.

The group in the trial

  • Solid Organ Transplant and Hematopoietic Stem Cell Transplant patients

    Solid Organ Transplant (SOT) and Hematopoietic Stem Cell Transplant (HSCT) patients with Ganciclovir Resistant or Refractory Cytomegalovirus infection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Epidemiological Burden of and Risk Factors for Ganciclovir Resistant/Refractory Cytomegalovirus in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Patients: Multicentre Cohort Study
Record updated
15 June 2026